Cardiff Oncology, Inc.
CRDF
$2.13
$0.094.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.26M | -13.94M | -13.43M | -11.79M | -11.86M |
| Total Depreciation and Amortization | 224.00K | 229.00K | 228.00K | 96.00K | 236.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.13M | 1.38M | 1.23M | 1.05M | 1.10M |
| Change in Net Operating Assets | -932.00K | 4.00M | -816.00K | 378.00K | 67.00K |
| Cash from Operations | -10.83M | -8.33M | -12.79M | -10.27M | -10.46M |
| Capital Expenditure | -18.00K | -26.00K | -- | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.18M | -4.96M | -14.58M | 4.51M | -9.43M |
| Cash from Investing | 10.16M | -4.98M | -14.58M | 4.51M | -9.43M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25.00K | 0.00 | 3.00K | 44.19M | 7.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.00K | 0.00 | 3.00K | 44.19M | 7.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -649.00K | -13.31M | -27.38M | 38.43M | -12.46M |